Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXS-12 (reboxetine) in narcolepsy with cataplexy and excessive daytime sleepiness
NCT05113745Phase 3Completed
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Oct 2021
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in narcolepsy comparing AXS-12 (reboxetine) with Placebo (2 arms). Primary endpoints: Treatment-Emergent Adverse Events at 28 weeks and Change in Frequency of Cataplexy Attacks at 27 weeks. Started Oct 2021; status: completed.
02
Drugs
reboxetine
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NCT05113745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05113745.